Ozempic semaglutide

Medicare currently covers GLP-1 medications only when prescribed for FDA-approved indications other than weight loss. Ozempic, Mounjaro, and Trulicity are covered for type 2 diabetes when medically indicated. Wegovy and Zepbound — both FDA-approved specifically for chronic weight management — are not covered by Medicare. The Treat and Reduce Obesity Act has been introduced in Congress to change this, but as of 2026 it has not become law. Medicare Advantage plans sometimes offer expanded coverage; check your specific plan documents. Medicaid coverage varies significantly by state.

GLP-1 receptor agonists mimic glucagon-like peptide-1, a gut hormone released after eating. They work through three main pathways: (1) Slowing gastric emptying — food stays in the stomach longer, prolonging fullness. (2) Suppressing appetite in the brain — they reduce the constant 'food noise' many patients describe, making it easier to eat smaller portions and skip snacks. (3) Improving insulin response — they enhance glucose-dependent insulin release, which helps with blood sugar control. Tirzepatide (Mounjaro/Zepbound) additionally activates GIP receptors, producing stronger appetite suppression and weight loss than GLP-1 alone in head-to-head trials.

Yes — most anesthesia societies now recommend holding GLP-1 medications (including Wegovy, Zepbound, Ozempic, Mounjaro) before procedures requiring general anesthesia or deep sedation. The American Society of Anesthesiologists guidance is to hold weekly GLP-1 injections for at least one week before an elective procedure to reduce aspiration risk from retained gastric contents. Daily GLP-1 medications (Saxenda, Rybelsus) are typically held the day of the procedure. Tell your anesthesiologist and surgeon at every preoperative appointment that you are on a GLP-1, even if you've held the dose — semaglutide has a long half-life and effects on gastric emptying can persist. For emergency surgery, hold is not possible; the anesthesia team will adjust technique accordingly. Restart timing post-op depends on the procedure and how you're tolerating diet.

Ozempic and Wegovy are both semaglutide — the same active ingredient made by Novo Nordisk. The differences: (1) FDA indication — Ozempic for type 2 diabetes (with cardiovascular risk reduction), Wegovy specifically for chronic weight management; (2) maximum dose — Ozempic tops out at 2mg weekly, Wegovy at 2.4mg, the dose used in the STEP weight-loss trials; (3) insurance coverage — Ozempic for T2D is broadly covered, Wegovy for weight loss is plan-dependent and often requires prior auth. Patients without diabetes who want semaglutide for weight loss typically need Wegovy (the on-label option). Off-label Ozempic for weight loss is widespread but insurance generally won't cover it. During Wegovy shortages (now resolved), many patients used Ozempic off-label as a workaround.

Yes — Medicare Part D covers Ozempic for its FDA-approved indication: type 2 diabetes with adequate glycemic control documentation. Coverage typically requires prior authorization with documented T2D diagnosis (A1c values, prior diabetes medications tried). Copay varies by plan tier — typically $30-100/month for Ozempic, with some plans placing it on a higher specialty tier. Medicare Part D does NOT cover Ozempic when prescribed off-label for weight loss in patients without diabetes (Medicare excludes anti-obesity medications by federal statute, even when prescribed off-label). Medicare Advantage plans sometimes offer slightly more permissive coverage; check your specific plan. The Treat and Reduce Obesity Act, introduced in Congress, would change weight-loss medication coverage rules for Medicare — as of 2026 it has not become law.

'Ozempic face' is a media-popularized term for the gaunt, hollow appearance some patients develop with significant rapid weight loss on GLP-1 medications. It's not Ozempic-specific or even GLP-1-specific — any rapid weight loss (bariatric surgery, severe diet) produces the same effect because facial fat pads shrink faster than skin can remodel. The 'face' specifically refers to loss of volume in the cheeks and under-eye area combined with looser skin. Prevention/mitigation strategies: slow the rate of weight loss (slower titration, lower maintenance dose), maintain adequate protein intake, hydrate, and consider building/maintaining muscle. Treatments range from cosmetic (dermal fillers, fat-transfer procedures, biostimulators) to behavioral (re-feeding when at a healthy weight to restore fat volume). The trade-off is personal — many patients prefer the face change to the prior weight, others find it bothersome enough to consider treatment.